Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight ...

Smith & Nephew has lowered its 2026 sales outlook after weakness in U.S. orthopedics and wound care outweighed stronger growth in sports medicine. | Smith & Nephew has lowered its 2026 sales outlook ...

A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for ...

Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate (ADC) from Alphamab Oncology, while adding another Big Pharma partner in the form of AstraZeneca. The deal with ...

Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer ...

Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion ...

Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate ...

“The question early on was what mechanisms we wanted,” Madrigal CEO Bill Sibold told Fierce in an interview at the company’s ...

Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with ...

BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso. The San Diego-based oncology outfit first outlined an ambition last month ...

One of the most closely-watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech. It’s been a six-month ...

Following a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted ...